Medicine that’s
RIGHT FOR OUR PATIENTS
Azurity specializes in providing safe, high-quality treatments for patients requiring customized formulations for their care.
Medicine that’s
RIGHT FOR OUR PATIENTS
Azurity specializes in providing safe, high quality treatments for patients requiring customized formulations for their care. Azurity focuses on the needs of patients, such as children and the elderly, requiring customized, user-friendly drug formulations.
Medicine that’s
RIGHT FOR OUR PATIENTS
Azurity specializes in providing safe, high quality treatments for patients requiring customized formulations for their care. Azurity focuses on the needs of patients, such as children and the elderly, requiring customized, user-friendly drug formulations.
Medicine That’s Easy to Give…
and to Take
Azurity’s products have benefited millions of patients who are unable to swallow conventional oral dosage forms, such as tablets and capsules, and whose needs are not served by other commercially available therapies.
Azurity currently offers a comprehensive product portfolio that serves multiple therapeutic areas, with more on the way!
FDA-APPROVED ORAL LIQUIDS
A growing portfolio of products designed to fulfill unmet needs of both pediatric and elderly patients.
Labels for representation purposes only
FIRST® UNIT-OF-USE COMPOUNDING KITS
A family of prescription compounding kits designed as an alternative to conventional dosage forms.
Labels for representation purposes only
Pharmacist to Pharmacist
Click below to access our USP RESOURCES TOOLKIT to help you navigate the ever-changing <795>, <797>, and <800> USP chapters.
News & Events
Katerzia™, the First and Only Amlodipine Oral Suspension, 1 mg/mL, is Now Commercially Available for Pediatric Patients 6 Years of Age and Older
WOBURN, Mass. (September 25, 2019) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care, announced today that Katerzia (amlodipine) Oral Suspension, 1...
Azurity All-Hands Company Meeting
WOBURN, Mass. (September 11, 2019) - This September two companies met and became one, Azurity Pharmaceuticals is the beginning of that new family. This was a time to meet and get to know each other and build as an organization. The combination of the two legacy...
FDA Approves Katerzia™, the First and Only Amlodipine Oral Suspension, 1 mg/mL, for Pediatric Patients 6 Years of Age and Older
WOBURN, Mass. (July 10, 2019) – Azurity Pharmaceuticals, a specialty pharmaceutical company that makes safe, high-quality treatments for patients requiring customized formulations for their care, announced today that the U.S. Food and Drug Administration (FDA) has...
Resources
Azurity Pharmaceuticals, Inc. was formerly known as known as CutisPharma, Inc., parent company of Silvergate Pharmaceuticals, Inc. Product labeling, packaging, and imagery are for representation purposes only and may reflect Azurity, CutisPharma, or Silvergate.
The Information contained herein, including product information, is intended only for residents of the United States.
© 2019-2020 Azurity Pharmaceuticals, Inc. All Rights Reserved. All Trademarks referred to are the property of their respective owners. WEB-AZ-2.0
